Pharma gets 4 extra years of monopoly pricing on genetic drugs

What it does

This bill extends the patent-like exclusivity period for certain drugs from 7 years to 11 years if they use genetically targeted technology—meaning drugs designed to work on specific genetic profiles. The extension applies to 'advanced drug products' that modulate gene function. This gives pharmaceutical companies a longer period during which generic competitors cannot enter the market for these drugs.

Why we flagged it

The bill's operative mechanism is a straightforward extension of market exclusivity for a defined class of drugs. It is not disguised, but the title 'Maintaining Investments in New Innovation' obscures the actual effect—a monopoly-pricing extension—by framing it as innovation support rather than a delay of generic competition.

What the text implies

• The 4-year exclusivity extension applies regardless of whether the genetic targeting represents genuine innovation or marginal modification of existing drugs, creating incentive to add genetic-targeting claims to existing therapies to qualify for extended exclusivity.
• Medicare and Medicaid, which serve elderly and low-income populations, will bear disproportionate cost burden during the extended exclusivity period, as these programs cover high volumes of prescription drugs and cannot easily negotiate prices during exclusivity.
• The definition of 'advanced drug product' references section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act; if that definition is broad, many drugs could qualify for the extension, multiplying the aggregate cost to consumers and public programs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and public insurers (Medicare, Medicaid) will face higher drug prices for an additional 4 years because generic competition is delayed. While genetic targeting may eventually benefit patients with specific conditions, the exclusivity extension is a direct transfer of wealth from consumers and taxpayers to pharmaceutical companies, with no offsetting public benefit stated in the bill.

Who stands to gain

• pharmaceutical companies developing genetically targeted drugs
• biotechnology firms with genetic-targeting platforms

Named in the bill

Social Security Act, Federal Food, Drug, and Cosmetic Act, Medicare, Medicaid, pharmaceutical industry, generic drug manufacturers

Where it stands

51 cosponsors: 44 Republicans, 7 Democrats.

• Feb 27, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 27, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

26 lobbying clients named this bill on 39 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $8,926,396 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Donald Davis, the sponsor, reported $1,617,446 in PAC receipts in the 2026 cycle. $7,000 of that came from 1 PAC tied to these lobbying clients.

• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Novartis — $1,410,000 on 1 filing
• Alnylam Pharmaceuticals, Inc. — $450,000 on 1 filing
• Harmony Biosciences — $360,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.